NVSNovartis PharmaceuticalsRunning, no new patients
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 63 (final count)
- Started
- May 5, 2023
- Main results expected
- Dec 2, 2024
- Fully finished
- Jan 13, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic progression free survival (rPFS)
Measured over: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 47 months (estimated final analysis)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-02, no fading
Raw record changes
- none yet
Trial ID NCT05658003 · record last updated 2026-03-23 · checked 2026-11-09 15:47 UTC